- Home
- RPAY vs CERS Comparison
RPAY vs CERS Comparison
Compare RPAY & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPAY | CERS |
|---|---|---|
| Founded | 2006 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.0M | 276.0M |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | RPAY | CERS |
|---|---|---|
| Price | $3.05 | $1.78 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $6.81 | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 06-09-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $309,261,000.00 | $51,326,000.00 |
| Revenue This Year | $0.22 | $20.00 |
| Revenue Next Year | $7.12 | $9.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $2.70 | $1.12 |
| 52 Week High | $5.98 | $2.96 |
Technical Indicators
Market Signals| Indicator | RPAY | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 32.87 |
| Support Level | $2.98 | $1.34 |
| Resistance Level | $3.87 | $2.26 |
| Average True Range (ATR) | 0.20 | 0.18 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 56.78 | 2.22 |
Price Performance
Historical ComparisonAbout RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.